<DOC>
	<DOCNO>NCT01696123</DOCNO>
	<brief_summary>Current therapeutic approach treatment neurodegenerative disease like Alzheimer disease ( AD ) offer limited often transient symptomatic benefit patient mitigate insidious loss neuronal cell . In trial investigator evaluate Efficacy Tolerability MLC601 neuroprotective Patients Mild Moderate Alzheimer Disease Were Unable Tolerate Failed Benefit Treatment Rivastigmine .</brief_summary>
	<brief_title>Efficacy Tolerability MLC601 Patients With Mild Moderate Alzheimer Disease Who Were Unable Tolerate Failed Benefit From Treatment With Rivastigmine</brief_title>
	<detailed_description>An 18-month open-label pilot study would conduct three university referral centre Tehran , Iran . All patient least 50 year old , meet criterion AD accord fourth edition Diagnostic Statistical Manual Mental Disorders ( DSM-IV ) , fail treatment cholinesterase inhibitor Rivastigmine reason . A baseline medical history take physical examination perform participant , comorbidities concomitant therapy would note . Patients control concomitant disease , hypertension diabetes , allow enter study . Mini-Mental State Examination ( MMSE ) 10 Alzheimer disease assessment scale-cognitive sub scale11 ( ADAS-cog ) use measure treatment efficacy . MLC601 prescribe one capsule three time daily without escalation dose . Safety tolerability evaluation include physical examination , electrocardiography , vital sign monitor laboratory test weekly first 8 week every 4 week thereafter . The MMSE ADAS-cog record efficacy follow-up visit .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>least 50 year old meet criterion AD accord fourth edition Diagnostic Statistical Manual Mental Disorders ( DSMIV ) fail treatment cholinesterase inhibitor Rivastigmine reason uncontrolled diabetes mellitus hypertension unstable cardiac disease severe obstructive pulmonary disease renal hepatic failure and/or life threaten condition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>Cholinesterase inhibitor</keyword>
	<keyword>MLC601</keyword>
	<keyword>NeuroAiD</keyword>
	<keyword>neuroprotection</keyword>
	<keyword>neuroregeneration</keyword>
</DOC>